论文部分内容阅读
目的:观察博利康尼、布地奈德雾化吸入治疗婴幼儿毛细支气管炎的临床疗效。方法:两组婴幼儿毛细支气管炎患儿均给予常规治疗,有心力衰竭者加用强心、利尿、扩血管治疗。治疗组在此基础上加用博利康尼溶液1 ml/次(含硫酸特布他林2.5 mg)、布地奈德0.5～1 mg,每日2～3次雾化吸入15 min/次,疗程5～7天。观察两组的疗效、主要症状与体征的消失时间及肺功能指标。结果:①治疗组的痊愈率和总有效率均明显高于对照组(P<0.05)。②治疗组患儿的咳嗽、气促、喘息、肺部哮鸣音及肺部啰音等症状、体征消失时间均短于对照组(P<0.05)。③治疗后两组的潮气量、吸呼比、达峰时间比、达峰容积比等肺功能指标均较治疗前明显改善,且治疗组较对照组改善更明显(P<0.05)。④两组在治疗过程中均未见明显不良反应发生。结论:博利康尼、布地奈德雾化吸入治疗婴幼儿毛细支气管炎能明显改善临床症状、体征及肺功能,无明显不良反应,值得临床推广使用。
Objective: To observe the clinical efficacy of nebulized budesonide and budesonide in the treatment of infantile bronchiolitis. Methods: Two infants with bronchiolitis were given routine treatment in children, with heart failure plus cardiac, diuretic, vasodilator therapy. On the basis of this, the treatment group was treated with the combination of BoliCalidi solution 1 ml / time (terbutaline sulfate 2.5 mg), budesonide 0.5 ~ 1 mg, atomization inhalation 15 min / time 2 ~ 3 times daily, 5 ~ 7 days. Efficacy of the two groups were observed, the main symptoms and signs of disappearance of time and lung function indicators. Results: ① The cure rate and total effective rate of the treatment group were significantly higher than that of the control group (P <0.05). ② The cough, shortness of breath, wheezing, lung wheezing and pulmonary rales in the treatment group were shorter than those in the control group (P <0.05). ③ After treatment, the indexes of lung function, such as tidal volume, respiration ratio, peak time ratio and peak volume ratio in both groups were significantly improved compared with that before treatment, and the treatment group improved more significantly than the control group (P <0.05). The two groups in the course of treatment were no obvious adverse reactions occurred. Conclusion: The treatment of infantile bronchiolitis with nebulized budesonide and budesonide can significantly improve clinical symptoms, signs and lung function without obvious adverse reactions and is worthy of clinical promotion.